Cardiovascular toxicities from systemic breast cancer therapy

Shuang Guo, Serena Wong

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Cardiovascular toxicity is unfortunately a potential short- or long-term sequela of breast cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and newer targeted agents such as trastuzumab can cause varying degrees of cardiac dysfunction. Type I cardiac toxicity is dose-dependent and irreversible, whereas Type II is not dose-dependent and is generally reversible with cessation of the drug. In this review, we discuss what is currently known about the cardiovascular effects of systemic breast cancer treatments, with a focus on the putative mechanisms of toxicity, the role of biomarkers, and potential methods of preventing and minimizing cardiovascular complications.

Original languageEnglish (US)
Article number346
JournalFrontiers in Oncology
Issue numberDEC
StatePublished - 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • Anthracycline
  • Breast cancer
  • Cardiotoxicity
  • Chemotherapy
  • Heart failure
  • Trastuzumab


Dive into the research topics of 'Cardiovascular toxicities from systemic breast cancer therapy'. Together they form a unique fingerprint.

Cite this